CLINICAL TRIALS AND OBSERVATIONS MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
نویسندگان
چکیده
1Hematologie biologique, Hôpital Saint Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France; 2Institut Universitaire d’hematologie, Hôpital Saint-Louis, Paris, France; 3Anatomie Pathologie, Hôpital Saint Louis, AP-HP, Paris, France; 4Institut Universitaire d’hématologie–Paris VII, Inserm U728, Paris, France; 5Hemato-oncology, Centre Hospitalier Universitaire (CHU) de l’Archet, Nice, France; 6Institute of Pathology, University of Wuerzburg (for Deutsche Studiengruppe Hochmaligne Non-Hodgkin-Lymphome [DSHNHL]), Wuerzburg, Germany; 7Pathology, Uppsala University Hospital, Uppsala, Sweden; 8Pathology, St Gallen Hospital (for Schweizerische Arbeitgeminschaft für Klinische Krebsforchnung [SAKK]), St Gallen, Switzerland; 9Inserm U533, Institut du thorax, Faculté de Médecine, Université de Nantes, Nantes, France; 10Service d’Hématologie, CHU Purpan, Toulouse, France; 11Service Hématologie, Institut Jules Bordet, Bruxelles, Belgium; 12Inserm U955, Créteil, France; 13Université Paris Est, Créteil, France; 14Department of Pathology, Hôpital Henri-Mondor, AP-HP, Créteil, France; 15Inserm U954, CHU de Nancy, Nancy, France; 16Groupe d’Etude des Lymphomes de l’Adulte (GELA), France; and 17Hematology, Hôpital Saint Louis, AP-HP, Paris, France
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
Second-line chemotherapy followed by high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) cures less than half of the patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Prognostic models capable of predicting outcome are essential. In 3 sequential clinical trials, conducted from January 1993 to August 2000, we treated 150 patients with relapsed or pr...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
This study was set up to demonstrate whether prognostic classification based on the secondary age-adjusted International Prognostic Index (sAA-IPI) for recurring aggressive non-Hodgkin lymphoma (NHL) or the prognostic score for recurring Hodgkin lymphoma (HL) can be improved by including the midtreatment results of fluorine-18-fluorodeoxy-glucose–positron emission tomography (FDG-PET). Clinical...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation
1Department of Hematology, Centre Hospitalier Universitaire (CHU) Lille, France; 2Christie Hospital, Manchester University, United Kingdom; 3Nuclear Medicine Division, European Institute of Oncology, Milan, Italy; 4Institute of Hematology “Seràgnoli,” University of Bologna, Italy; 5Derriford Hospital, Plymouth, United Kingdom; 6Policlinico Monteluce, Perugia, Italy; 7University Hospital of Bord...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
Mantle-cell lymphoma (MCL) is characterized by poor prognosis with a median survival of only 3 to 4 years. To improve clinical outcome, the European MCL Network initiated a randomized trial comparing consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation (ASCT) to interferon maintenance (IFN ) in first remission. Patients 65 years of age or younger w...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma
Feasibility, safety, and efficacy of a 4-course high-dose chemotherapy (HDT) protocol including autologous stem cell transplantation (SCT) after courses 2, 3, and 4 was investigated in 110 patients, aged 18 to 60 years, with primary diagnosis of aggressive NHL (aNHL), and lactic dehydrogenase (LDH) levels above normal. At dose level 1 (DL1), course 1 consisted of cyclophosphamide 1500 mg/m2, do...
متن کامل